News

New follow-up data from the EARLY TAVR trial demonstrate continued clinical benefits of transcatheter aortic valve replacement in patients with asymptomatic severe aortic stenosis. The updated results reinforce the safety and efficacy of early intervention before symptom onset in this patient population.

Digest: These findings support expanding TAVR utilization to asymptomatic patients with severe AS, potentially shifting treatment paradigms and increasing the addressable patient population for structural heart programs.

Transcatheter aortic valve replacement using an Edwards Lifesciences valve system demonstrated encouraging outcomes in patients with severe aortic regurgitation. The data suggest TAVR may be a viable treatment option for this traditionally surgical patient population.

Digest: Severe AR has been a relative contraindication for TAVR due to anatomical challenges, and positive data could expand the treatment population and market for Edwards' valve technology.

The SMART trial's 3-year results showed that self-expanding supra-annular TAVR valves (Evolut platform, Medtronic) demonstrated superior hemodynamics and less thrombosis compared to balloon-expandable valves (Sapien platform, Edwards Lifesciences) in patients with small aortic annuli (≤430 mm²). There was no difference in the composite clinical endpoint of mortality, disabling stroke, or heart failure rehospitalization between groups (self-expanding 25.4% vs balloon-expandable 22.6%; HR 1.13, 95% CI 0.83-1.53, P=0.44).

Digest: These extended follow-up data support the use of self-expanding supra-annular valves for improved hemodynamic performance in small annuli patients, particularly relevant for lower-risk and younger TAVR candidates where long-term valve function is critical.

New data confirm that single antiplatelet therapy (SAPT) after transcatheter aortic valve replacement demonstrates key clinical benefits compared to dual antiplatelet therapy (DAPT). The findings support a streamlined antithrombotic strategy that may reduce bleeding complications while maintaining efficacy.

Digest: This evidence could influence anticoagulation management protocols post-TAVR, potentially reducing bleeding risk and healthcare costs while simplifying patient management for the growing TAVR population.

A new meta-analysis demonstrates that conduction system pacing following transcatheter aortic valve replacement is associated with improved clinical outcomes compared to conventional right ventricular pacing. The analysis suggests conduction system pacing may be a preferred pacing strategy for TAVR patients requiring permanent pacemaker implantation.

Digest: This finding could influence pacing strategy selection in the significant proportion of TAVR patients who develop conduction abnormalities requiring permanent pacemaker, potentially reducing long-term morbidity associated with right ventricular pacing.

The PRAISE-MR randomized trial evaluated angiotensin receptor neprilysin inhibitor (ARNI) therapy in patients with heart failure with preserved ejection fraction (HFpEF) and secondary mitral regurgitation. The study assessed whether ARNI treatment could reduce mitral regurgitation severity and improve clinical outcomes in this patient population.

Digest: This trial addresses whether medical therapy with ARNI can reduce secondary MR in HFpEF patients, potentially identifying responders who may avoid transcatheter mitral intervention versus non-responders who require TMVR.

Three-year follow-up data from the SMART trial continues to demonstrate superior structural valve deterioration outcomes for self-expanding TAVR valves compared to balloon-expandable systems. The durability advantage of self-expanding valves persisted at the 3-year time point.

Digest: This extends evidence supporting differential long-term durability between TAVR platform designs, which is critical for valve selection decisions particularly in younger, lower-risk patients where long-term performance drives clinical and economic outcomes.

Cerebral embolic protection devices designed to prevent stroke during transcatheter aortic valve replacement procedures have failed to demonstrate clinical benefit in trials and real-world use. Despite mechanistic rationale and debris capture evidence, these devices have not shown reduction in stroke rates or neurocognitive outcomes, limiting their adoption in routine TAVR practice.

Digest: The lack of clinical efficacy for stroke prevention devices leaves periprocedural stroke as an unresolved complication of TAVR, affecting patient counseling, procedural risk assessment, and development priorities for next-generation protective technologies.

A study demonstrates that women undergoing transcatheter aortic valve replacement (TAVR) experience longer survival compared to men following the procedure. This sex-based difference in post-TAVR mortality represents an important outcome disparity in structural heart interventions.

Digest: Understanding sex-specific outcomes after TAVR is critical for risk stratification, patient selection, and informed consent discussions, particularly as TAVR expands into lower-risk and younger patient populations.

A study found that GLP-1 receptor agonist weight loss medications were associated with clinical benefits in patients undergoing transcatheter aortic valve replacement (TAVR) and percutaneous coronary intervention (PCI). Specific outcome data including mortality, cardiovascular events, or procedural success rates were not detailed in the provided excerpt.

Digest: GLP-1 agonist use may influence risk stratification and periprocedural optimization strategies for TAVR candidates, particularly in obese or diabetic populations.

A five-year comparative study found that redo surgical mitral valve replacement outperformed transcatheter valve-in-valve mitral replacement for failed bioprosthetic mitral valves. The superior long-term outcomes of redo surgery over the transcatheter approach challenge current treatment preferences for this patient population.

Digest: This data may influence decision-making between redo surgical MVR and transcatheter valve-in-valve procedures, particularly in patients with acceptable surgical risk and longer life expectancy.

Early surgical aortic valve replacement (SAVR) in asymptomatic patients with aortic stenosis demonstrated long-term clinical benefits compared to conservative management. The study suggests intervention prior to symptom onset may improve outcomes in select patients with severe AS.

Digest: This challenges the traditional watchful waiting approach for asymptomatic severe AS and may influence guideline recommendations regarding timing of intervention in this patient population.

University of Colorado Hospital's Heart and Vascular Center performs approximately 3,000 interventional and structural heart procedures annually, including complex PCI with hemodynamic support and transcatheter mitral valve repair. The program has participated in pivotal trials for structural heart devices and performs 25-50 chronic total occlusion procedures and 50 Impella-supported high-risk PCI cases per year.

Digest: This academic center's experience with MitraClip procedures, complex high-risk PCI, and participation in pivotal device trials provides insights into advanced structural heart program development and procedural volumes at high-performing institutions.